Practical Strategies for Improving
Diagnosis and Treatment of PAH

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Gilead Sciences and Actelion

Pulmonary Arterial Hypertension (PAH) is a very serious, life threatening condition that worsens over time and for which there is no cure. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis. PAH is a progressive vascular disorder where continuous, exceedingly high blood pressure exists in the pulmonary artery – the blood vessel that carries blood from the right ventricle of the heart into the small arteries in the lungs. As arteries narrow, they are more resistant to blood flow, which can cause stiffening or even the formation of tiny blood clots, sometimes causing blockages as the heart works harder to pump blood into the lungs. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure – the most common cause of death for PAH patients. Additionally, PAH often leads to several co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing the disease and its associated costs.

Upon Completion of this activity, participants will be able to:

  • Analyze the current guideline recommendations on treatment goals for patients with PAH

  • Identify signs and symptoms of PAH to appropriately utilize guideline recommended tools to diagnose, stage, and set personalized treatment plans for each patient

  • Explore the best ways to adjust treatment for those PAH patients who are not responding to their initial treatment plan

  • Discuss recent advances in pharmacologic therapies and monitor disease progression, including side effects, comorbidities and adherence in patients with PAH

  • Recognize effective healthcare provider-patient communication strategies to improve treatment outcomes for patients with PAH

Faculty: Franck Rahaghi, MD, MHS, FCCP
Director, Pulmonary Hypertension Clinic
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida


Dr. Rahaghi serves on an advisory board for Actelion, Bayer, Gilead and United Therapeutics. He serves as a consultant for Actelion, Bayer, Gilead and United Therapeutics. He has received research/grant support from Actelion, Bayer, Gilead and United Therapeutics. He serves on the speaker's bureau for Actelion, Bayer, Gilead and United Therapeutics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Gilead Sciences and Actelion

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue